FDA Brief

Warning letters Drugs

FDA warning letter to

AlzClipp / UniUni

High riskIssued Jul 29, 2025Posted Aug 26, 2025Center for Drug Evaluation and Research (CDER)

FDA warns AlzClipp/UniUni that its AlzClipp nasal product is an unapproved new drug and misbranded with false FDA approval claims.

What happened

FDA reviewed the company's product labeling and website at alzclipp.com in July 2025 and found the AlzClipp nasal product offered for sale in the United States. The label and website claim the product boosts memory, prevents Alzheimer's disease, reverses dementia, and treats memory decline. FDA also found an FDA logo with 'FDA approved' and a certificate headline saying 'FDA Approves AlzClipp' even though there is no FDA-approved application for the product.

What FDA found

  1. AlzClipp is a drug because its label and website claim it prevents or treats Alzheimer's disease, dementia, and memory decline.

    section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  2. AlzClipp is an unapproved new drug because there is no FDA-approved application for it.

    sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d); section 201(p), 21 U.S.C. 321(p)
  3. The website is false or misleading because it uses an FDA logo and says 'FDA approved' and 'FDA Approves AlzClipp' even though FDA has not approved the product.

    section 502(a) of the FD&C Act, 21 U.S.C. 352(a); section 301(a), 21 U.S.C. 331(a)

What FDA wants

FDA tells the company to notify FDA in writing within 15 working days of receipt of the letter about specific steps taken to correct the violations and prevent recurrence. If the company believes the product is not in violation, it must include its reasoning and supporting information.

Who should pay attention

  • companies selling nasal or cognitive-health products with disease claims
  • online retailers and marketplaces listing unapproved drugs
  • labeling and advertising reviewers who check FDA approval claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk